SI-BONE Q4 revenue rises

SI-Bone

23/02/2026 21:17

Overview

Bone solutions firm's Q4 revenue grew 15%, slightly beating analyst expectations

Company achieved positive adjusted EBITDA of $5.1 mln, improving by 176.2%

Outlook

SI-BONE expects 2026 revenue between $228.5 mln and $232.5 mln, ~14% to ~16% growth

Company estimates 2026 gross margin to be approximately 78%

SI-BONE expects increased positive adjusted EBITDA for full year 2026

Result Drivers

PHYSICIAN ENGAGEMENT - Increase in U.S. physicians performing procedures contributed to revenue growth

STRATEGIC PARTNERSHIP - Partnership with Smith+Nephew to distribute products in trauma centers supported growth

PRODUCT EXPANSION - Launch of INTRA Ti enhanced procedural flexibility and efficiency in surgery centers

Company press release: ID:nGNX4bZ7fZ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Beat*
$56.35 mln
$55.93 mln (6 Analysts)
Q4 Net Income
-$1.65 mln
Q4 Gross Margin
79%
Q4 Basic EPS
-$0.04
Q4 Operating Expenses
$46.99 mln
Q4 Operating income
-$2.46 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for SI-BONE Inc is $25.00, about 61.5% above its February 20 closing price of $15.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)